Key clinical point: In patients with chronic hepatitis B virus (HBV) infection who have undergone curative liver resection for hepatocellular carcinoma (HCC), concurrent metabolic syndrome is associated with poorer long-term oncological outcomes.
Major finding: Patients with vs without metabolic syndrome had significantly lower 5-year overall survival (OS; P = .010) and recurrence-free survival (RFS; P = .003) rates and higher 5-year overall recurrence rate ( P = .024). Concurrent metabolic syndrome was independently associated with poorer OS (adjusted hazard ratio [aHR] 1.300; P = .036) and RFS (aHR 1.314; P = .012) rates and increased late recurrence rate (aHR 1.470; P = .047).
Study details: Findings are from a multicenter cohort study including 1753 patients who underwent liver resection for HBV-related HCC, of which 163 patients had concurrent metabolic syndrome.
Disclosures: This study was funded by the National Natural Science Foundation of China, among others. No information on conflicts of interest was available.
Source: Wang MD et al. Association of concurrent metabolic syndrome with long-term oncological prognosis following liver resection for hepatocellular carcinoma among patients with chronic hepatitis B virus infection: A multicenter study of 1753 patients. Ann Surg Oncol. 2022 (Sep 16). Doi: 10.1245/s10434-022-12529-6